Design of the Randomized, Placebo-Controlled Evolocumab for Early Reduction of LDL-Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS) Trial. by Koskinas, Konstantinos C et al.
A
cc
ep
te
d 
A
rti
cl
e
Design of the Randomized, Placebo-Controlled Evolocumab for Early Reduction of LDL-
Cholesterol Levels in Patients with Acute Coronary Syndromes (EVOPACS) Trial  
 
Konstantinos C. Koskinas, MD
a
, Stephan Windecker, MD
a
, Aliki Buhayer
b
, Baris Gencer, MD
c
, 
Giovanni Pedrazzini, MD
d
, Christian Mueller, MD
e
, Stephan Cook, MD
f
, Olivier Muller, MD
g
, 
Christian M. Matter, MD
h
, Lorenz Räber, MD, PhD
a
, Dik Heg, PhD
i
, François Mach, MD
c
, on behalf 
of the EVOPACS investigators   
 
a
Department of Cardiology, Bern University Hospital, Bern, Switzerland 
b
PRISM Scientific, Sàrl 
c
Department of Cardiology, Geneva University Hospital, Geneva, Switzerland 
d
Cardiocentro, Lugano, Switzerland  
e
Department of Cardiology and Cardiovascular Research Institute Basel, University Hospital Basel, 
Switzerland. 
f
Department of Cardiology, Fribourg Hospital and University, Switzerland  
g
Service of Cardiology, Lausanne University Hospital, Lausanne, Switzerland 
h
Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland
 
i
CTU Bern, University of Bern, Bern Switzerland 
 
 
 
Keywords: Acute coronary syndrome, PCSK9 inhibitor, Lipidology  
 
 
 
 
 
 
 
 
 
 
Corresponding author: 
Konstantinos C. Koskinas, MD, MSc, FESC 
Department of Cardiology 
Ben University Hospital 
Bern, Switzerland 
Tel: +41 31 632 42 15    
Fax: +41 21 632 89 77  
Email: Konstantinos.koskinas@insel.ch   
  
This article is protected by copyright. All rights reserved.
 
 
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which 
may lead to differences between this version and the Version of Record. Please cite this 
article as doi: 10.1002/clc.23112 
  so
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
2
1
2
7
3
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
A
cc
ep
te
d 
A
rti
cl
e
ABSTRACT 
 
Statins lower low-density lipoprotein cholesterol (LDL-C) and improve clinical outcomes in patients 
with atherosclerotic cardiovascular disease (CVD). Patients with acute coronary syndromes (ACS) 
often do not achieve LDL-C targets despite potent statin treatment, and have a particularly high risk 
of early recurrent events. Evolocumab, a proprotein convertase subtilisin/kexin type (PCSK9)-
inhibitor resulting in rapid, marked LDL-C reduction, has been studied in hypercholesterolemic 
subjects without CVD and stabilized patients with CVD; the feasibility, safety, and efficacy of this 
treatment initiated in the acute phase of ACS remain unknown. We report the design of Evolocumab 
for Early Reduction of LDL-Cholesterol Levels in Patients with ACS (EVOPACS), a phase-3, 
multicenter, randomized, double-blind, placebo-controlled trial to assess the feasibility, safety, and 
LDL-C-lowering efficacy of evolocumab on top of atorvastatin 40 mg in patients with ACS. The 
primary endpoint is percent change in LDL-C from baseline to 8 weeks. Secondary endpoints are 
adverse events and serious adverse events. Against a background of beneficial cardiovascular effects 
of statins beyond LDL-C lowering and in view of preclinical evidence of similar effects of PCSK9 
inhibition, the study will also address a variety of exploratory endpoints including the change in C-
reactive protein and other inflammatory biomarkers; platelet reactivity; and occurrence of contrast-
induced acute kidney injury and myocardial injury in patients undergoing cardiac catheterization. An 
intracoronary imaging sub-study will assess the change from baseline in the lipid core burden index in 
non-culprit lesions, as assessed by serial near-infrared spectroscopy. Recruitment began in January 
2018 and enrolment of 308 patients is planned.  
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INTRODUCTION 
Patients with acute coronary syndromes (ACS) have an increased risk of recurrent ischemic events.
1
 
Lowering of low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular morbidity and 
mortality in patients with atherosclerotic cardiovascular disease (CVD).
2
 In the context of ACS, 
statins – the accepted standard of care for LDL-C lowering – result in early, sustained clinical 
benefit
3-5
 and their early initiation in patients presenting with ACS is recommended in current 
guidelines.
1,6
 In patients who cannot achieve sufficient LDL-C lowering with statins, non-statin 
medications are a valuable add-on option. Proprotein convertase subtilisin/kexin type 9 (PCSK9) 
inhibitors represent a promising approach for rapid, profound reduction in LDL-C and incremental 
reduction of cardiovascular morbidity.
7-9
 As statins have a delayed onset of action before target levels 
are attained and the risk of event recurrence is highest during the first weeks after ACS, PCSK9 
inhibitors may be of potential therapeutic interest in this particular setting. Two clinically approved 
anti-PCSK9 antibodies, evolocumab and alirocumab, have been evaluated in hypercholesterolemic 
patients without CVD, stable ischemic heart disease, or stabilized patients with a history of ACS.
7,8
 
Treatment with PCSK9 inhibitors has not been studied in the very high-risk, acute (within days) 
setting of ACS.   
 In addition to lowering LDL-C, statins exert vasculoprotective effects including reduction of 
plasma levels of inflammatory biomarkers,
10
 stabilization of coronary plaque morphology,
11,12
 
attenuation of platelet reactivity,
13
 prevention of myocardial injury
14
 and contrast-induced kidney 
injury
15
 in patients undergoing coronary interventions. These favorable effects are of particular 
relevance in the acute context of ACS, as the residual ischemic risk and high event recurrence are 
likely related to the enhanced pro-inflammatory and pro-thrombotic milieu. The PCSK9 enzyme is 
expressed in atherosclerotic plaques,
16
 implicated in vascular inflammation,
17
 and may affect platelet 
function and thrombogenicity according to preclinical evidence.
18 
Whether these mechanistic effects 
might translate to favorable clinical effects of PCSK9 inhibition beyond the potent LDL-lowering 
efficacy remains largely unknown.   
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Against this background, we designed a randomized, placebo-controlled trial to assess the 
feasibility, safety, and LDL-lowering efficacy of evolocumab administered within 24-72 hours of 
symptom onset in patients presenting with ACS. Moreover, the EVOPACS study will assess the 
impact of evolocumab on a variety of exploratory endpoints including inflammatory biomarkers, 
platelet reactivity, coronary plaque composition, as well as myocardial and acute kidney injury 
following coronary interventions. Exploring these mechanistic aspects in the very high-risk clinical 
setting of ACS may help identify additional early effects of PCSK9 inhibitors.     
 
METHODS   
Study Design  
EVOPACS is an investigator-initiated, prospective, randomized, double-blind, placebo-controlled, 
parallel-group, multi-center trial (http://www.clinicaltrial.gov NCT03287609). The study evaluates 
the feasibility, safety and efficacy of evolocumab for very early LDL-C lowering in ACS patients 
with LDL-C levels that are either above guideline-recommended targets
6
, or are not projected to be 
reduced below these targets under high-intensity statin therapy. Enrolment of 308 patients is planned 
at 7 centers in Switzerland. The trial began enrolment in January 2018. The protocol was approved by 
the institutional ethics committees, and written informed consent will be obtained from all study 
participants.   
Patients hospitalized for ACS, according to current definitions
1 
[non-ST-elevation myocardial 
infarction (NSTEMI) or unstable angina with onset <72h; or ST-elevation myocardial infarction 
(STEMI) with onset <24h] are potentially eligible. Screening is performed in medically stabilized 
patients as soon as possible upon patient admission, and LDL-C (fasting or non-fasting) is measured 
to determine eligibility. Patients who fulfil all eligibility criteria and provide informed consent are 
enrolled and randomly assigned to either evolocumab 420mg subcutaneously (sc) every 4 weeks or 
matching placebo sc. Clinical visits are scheduled at 4 and 8 weeks. The investigational product (IP) 
(evolocumab or placebo) is administered at the study site at 2 time points: at baseline (index ACS 
event) and after 4 weeks. The study endpoints are assessed at 8 weeks (Figure 1).   
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Previous studies have shown regression of coronary plaque volume and stabilization of 
plaque composition following intensive statin treatment.
19
 In the YELLOW trial, short-term (7-week) 
treatment with high-intensity statin reduced the lipid content of obstructive coronary lesions, as 
assessed by means of near-infrared spectroscopy (NIRS).
11 
Against this background, an exploratory 
intracoronary imaging sub-study will assess changes in the lipid core burden index (LCBI) of 
obstructive, non-culprit coronary lesions by means of serial NIRS performed at baseline and at 8 
weeks. A subset of selected patients who are enrolled in pre-selected study centers; undergo clinically 
indicated percutaneous coronary intervention (PCI) of the culprit lesion of the index ACS; and fulfil 
all additional eligibility criteria will be enrolled in the sub-study.   
Inclusion and Exclusion Criteria 
Inclusion criteria are summarized in Table 1. Briefly, LDL-C at screening needs to be (i.) above the 
guideline-recommended target level of 1.8mmol/l in patients previously treated with high-intensity 
statin (atorvastatin ≥40mg/day; rosuvastatin ≥20mg/day; or simvastatin 80mg/day) for at least 4 
weeks prior to enrolment; (ii.) >2.3 mmol/l in patients previously treated with low/moderate intensity 
statin; or (iii.) >3.2 mmol/l in patients previously not treated with statin. The rationale for selecting 
these cut-offs is that, for any status of prior statin treatment, LDL-C is not projected to reach the 
guideline-recommended target despite treatment with the study-specific background statin 
(atorvastatin 40mg). These cut-offs are based on previous evidence of the LDL-lowering efficacy of 
atorvastatin 40mg either as newly-initiated statin, or in the context of uptitration of a lower-intensity 
statin regimen.
6
 The main exclusion criteria are listed in Table 2.     
Additional criteria apply for the imaging sub-study (Appendix Table 1 and 2), mainly 
including the presence of a non-culprit de novo coronary lesion with angiographically significant 
stenosis at baseline (defined by ≥50% angiographic diameter stenosis by visual estimation) that is 
deemed suitable for treatment in a staged PCI procedure after 8 weeks. Patients with three-vessel or 
left-main coronary artery disease or those with a history of coronary artery bypass surgery are 
excluded from the sub-study.  
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Study Objectives and Endpoints   
The study’s primary objective is to assess the effectiveness of evolocumab compared with placebo, 
administered during the acute phase of ACS, for the reduction of LDL-C levels at 8 weeks in patients 
receiving atorvastatin 40mg. Evaluation of the safety of evolocumab administration in the clinical 
setting of early ACS is the secondary objective. The primary endpoint is the percent change in LDL-C 
from baseline to 8 weeks. The incidence of adverse events (AEs) and serious adverse events (SAEs) 
from baseline to 8 weeks is the secondary endpoint.  
Exploratory endpoints include (i.) lipid parameters: change from baseline in total cholesterol, 
high-density lipoprotein (HDL)-C, triglycerides, non-HDL-C, apolipoprotein B (ApoB), 
apolipoprotein A1 (ApoA1), lipoprotein(a), and percent of patients attaining the LDL-C goal <1.8 
mmol/l; (ii.) inflammatory biomarkers: change in high-sensitivity C-reactive protein (hs-CRP) and 
other biomarkers of inflammation, percentage of patients attaining the target of hs-CRP <2 mg/dl or 
the dual target of LDL-C (<1.8 mmol/l) and hs-CRP (<2 mg/dL) at 8 weeks; (iii.) incidence of 
contrast-induced acute kidney injury (CI-AKI) in patients who undergo diagnostic coronary 
angiography (with or without PCI); (iv.) change in high-sensitivity troponin T from baseline to 72 
hours; (v.) change in platelet reactivity assessed by impedance aggregometry (Multiplate Analyzer®) 
in whole blood stimulated with the ADP and TRAP tests between baseline and 8 weeks. Moreover, 
the incidence of centrally adjudicated events [death, cardiovascular death, myocardial infarction (re-
infarction), hospitalization for recurrent ACS, hospitalization for heart failure, coronary 
revascularization, stroke, or transient ischemic attack] will be assessed by an independent Clinical 
Events Committee blinded to patient treatment allocation.   
 The objective of the exploratory imaging sub-study is to evaluate the effect of evolocumab on 
the change in plaque lipid content as defined by serial NIRS, in non-culprit coronary lesions in 
patients who present with ACS and receive guideline-recommended high-intensity statin therapy 
(atorvastatin 40mg). The exploratory endpoints of the sub-study are change in total LCBI, and change 
in maximum LCBI in any 4-mm segment (maxLCBI4mm) from baseline to 8 weeks.   
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Treatments and Key Procedures 
Patients enrolled in the study will be treated for the ACS event in accordance with current 
guidelines.
1,20
 Patient management may include either medical treatment alone without invasive 
management; or coronary angiography if deemed clinically applicable, possibly followed by PCI or 
coronary artery bypass surgery. Dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 
inhibitor will be started as early as possible in all patients. Consistent with current recommendations 
and in order to reduce the confounding effect of differing antiplatelet treatments on the exploratory 
endpoint of platelet function, ticagrelor will be the P2Y12 inhibitor of choice, unless contra-indicated 
according to clinical judgment. DAPT will be continued at maintenance doses (aspirin ≤100mg/day, 
ticagrelor 90mg twice daily) for a duration that is determined by treating physicians, typically lifelong 
for aspirin and 12 months for ticagrelor. Guideline-recommended medical therapy, including beta-
blockers and ACE inhibitors will be administered as appropriate.    
After patient enrolment, randomization (based on computer-generated random numbers and 
using a central randomization system) is done in a double-blind fashion with 1:1 allocation. 
Randomization is stratified according to (i.) study center and (ii.) presence of unchanged statin 
treatment within ≥ 4 weeks prior to enrolment. Study patients, investigators, and study site personnel 
remain blinded to treatment allocation during the entire study duration.  
The IP is administered in 3 consecutive subcutaneous injections at 2 time-points (Figure 1). 
At baseline, the IP is administered as early as possible following randomization. Among patients who 
undergo clinically indicated coronary angiography (with or without revascularization), IP 
administration should occur prior to the index coronary angiography whenever possible, but IP 
administration after coronary angiography is also possible. Blood draws are performed at baseline for 
measurements of the primary as well as exploratory endpoints (“T0 measurements”). A subsequent 
blood draw is performed 72 hours later (within an allowed time window of 48-96 hours) for the 
measurement of kidney function (assessment of CI-AKI); high-sensitivity troponin T (assessment of 
PCI-related myocardial injury); and platelet function testing (“T72 measurements”). The second IP 
administration is performed during the 4-week visit, and blood draws are performed at the 4-week and 
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8-week visits (Figure 1). Patients are encouraged to complete the planned visits regardless of their 
adherence to IP administration [intention-to-treat (ITT) approach].   
All patients will receive background treatment with atorvastatin 40mg/day throughout the 
study period. This statin regimen is consistent with current guidelines recommending a high-intensity 
statin in patients presenting with ACS.
6 
Because a proportion of patients are expected to be statin-
naïve at the time of enrolment, and because – unlike previous studies with PCSK9 inhibitors – there is 
no run-in period for optimizing statin treatment, we refrained from selecting the highest (80mg) dose 
of atorvastatin in order to mitigate the potential of statin-related adverse effects and increase 
compliance. If patients were on a different statin regimen prior to enrolment, this is discontinued and 
replaced by atorvastatin 40mg. For patients who had been on a more potent statin regimen prior to 
enrolment (i.e., atorvastatin >40mg or rosuvastatin >20mg/day), the background therapy throughout 
the study period will be atorvastatin 80mg/day. Dose reduction or cessation of atorvastatin is allowed 
in the event of postulated side effects (e.g. muscular pain) or elevation of creatine kinase levels.  
For the intracoronary imaging sub-study, baseline NIRS is performed immediately following 
successful PCI of the culprit lesion at the time of the index ACS event. Follow-up NIRS imaging of 
the same vessel is performed at 8 weeks, prior to attempting a staged PCI in the non-culprit lesion. 
NIRS recordings will be analyzed by investigators unaware of treatment allocation.    
 Statistical Analyses  
This is a superiority trial powered for the primary endpoint. Assuming an average percentage LDL-C 
reduction of 30% in the control arm (placebo sc plus atorvastatin 40mg) and 44% in the active 
treatment arm (evolocumab sc plus atorvastatin 40mg), and adopting a common standard deviation of 
36%, a total sample size of 280 patients would provide statistical power of 90% at a significance level 
of 5% for a two-sided t-test. Anticipating a dropout rate of 10% at 8 weeks, a total of 308 patients 
should be recruited (154 per arm). The imaging sub-study is not powered and will aim at enrolling 50 
patients.    
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Analysis of primary endpoints: Efficacy and safety analyses will be performed on the full 
analysis set, which includes all randomized patients who have received at least one dose of the 
study IP. The primary analysis will be performed when all randomized subjects either have 
completed the scheduled study visits or have withdrawn early from the study; at that time point the 
study will be unblinded. Analysis of the primary endpoint will be conducted with a linear mixed 
effects model adjusting for the following stratification factors: (i) presence of unchanged statin 
treatment within ≥ 4 weeks prior to enrolment as a fixed effect; and (ii) study center as a random 
effect. Analysis will be based on the ITT principle and patients will contribute to the group to 
which they were randomized. Patients with missing data for the primary end-point will be 
excluded from the primary analysis. A key sensitivity analysis for the primary endpoint, using 
multiple imputation, will be carried out to assign the primary endpoint if follow-up (week 8) 
values are missing in more than 5% of patients. The superiority of evolocumab vs. placebo will be 
assessed for all efficacy endpoints, without applying multiplicity adjustments.   
Safety analyses: For analyses of safety outcomes, missing data will not be imputed, and adverse 
events (AE) will be summarized by treatment group using descriptive statistics. For analyses of 
clinical endpoints, patient incidence of events will be summarized for each randomized treatment 
group. 
Analyses of exploratory endpoints: A similar approach as for the primary endpoint will be used 
for the analysis of continuous exploratory outcomes defined as percentage changes. For 
continuous exploratory outcomes defined as nominal changes, mixed effects (with the study center 
as a random effect) linear models will be employed with the follow-up measurement as a response, 
and with the following explanatory variables: the corresponding baseline measurement; arm 
(binary variable); and presence of unchanged statin treatment within ≥ 4 weeks prior to enrolment 
(binary variable). For binary exploratory endpoints, differences will be assessed using Fisher’s 
exact test.   
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Covariates and subgroups: The following baseline covariates may be used for subgroup or 
covariate analyses: unchanged statin treatment within ≥ 4weeks prior to enrolment (yes / no); 
clinical presentation with STEMI vs. NSTE-ACS; age: < 65 vs. ≥ 65 years; gender; baseline LDL-
C: < median vs. ≥ median. Sensitivity analyses will be performed for exploratory outcomes 
influenced by the performance of coronary angiography (with or without PCI). More specifically, 
sensitivity analysis for the exploratory endpoint CI-AKI will be performed in the subgroup of 
patients who undergo coronary angiography at baseline, and will be stratified in relation to IP 
administration before vs. after coronary angiography. Similarly, sensitivity analysis for the 
exploratory endpoint change in hs-troponin T will be performed in the subgroup of patients who 
undergo PCI at baseline and will be stratified in relation to IP administration before vs. after PCI.    
The study protocol is a collaborative effort of the Steering Committee (KCK, SW and FM). 
The Clinical Trials Unit Bern, an academic research organization, will monitor the progress of the 
trial, have full access to the complete database, and independently generate all analyses. The Steering 
Committee will be responsible for submitting the results of the study for publication. The authors are 
solely responsible for drafting all related manuscripts and for their final content.  The study is funded 
by Amgen. 
 
RESULTS  
On October 25, 2018, a total of 180 patients had been enrolled in the study (mean age 61.1 ± 11.8 
years, 17% women). The majority of patients (77%) had been on no statin prior to enrolment, whereas 
12% had been on low- or moderate-intensity and 11% on high-intensity statin. The index ACS event 
was NSTE-ACS in 65% and STEMI in 35% of patients.   
 
DISCUSSION 
Patients with ACS remain at a high risk of recurrent events, namely MI, stent thrombosis and repeat 
revascularization, despite effective contemporary treatments;
1
 the residual ischemic risk may be 
related to the culprit lesion responsible for the index event, disease progression originating from non-
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culprit lesions
21
, or the increased inflammatory and platelet activation in the acute setting of ACS.
22
 
Lowering LDL-C levels with statins improves cardiovascular outcomes in patients with established 
CVD,
2
 and achievement of very low levels (below guideline-recommended targets) with more 
intensive statin therapy or with the addition of non-statin medications results in an incremental 
reduction in nonfatal events.
2,7,8
 In the very high-risk setting of ACS, the clinical benefit conferred by 
early implementation of intensive statin therapy is observed in the very early phase following the 
index ACS event – within 4 weeks of treatment in the PROVE-IT trial
3
 and within 16 weeks in the 
MIRACLE trial.
4
 However, statins have a delayed onset of action before target levels are attained 
which may be of importance, as the risk of event recurrence is highest during the first weeks after the 
acute phase of ACS. Moreover, many patients with ACS cannot achieve recommended targets of 
LDL-C despite potent statin treatment.
23
 Thus, there is an unmet need for patients who present with 
ACS and are not likely to achieve adequate LDL-C reduction with current oral lipid-modifying 
medications. Pharmacologic inhibition of PCSK9 has emerged as an effective treatment for properly 
selected patients as it results in rapid, profound reductions in LDL-C levels independently of 
background lipid-lowering therapies. Treatment with PCSK9 inhibitors initiated within a median of 3 
months or 3.4 years after an ACS has been investigated in 2 large outcomes studies of alirocumab and 
evolocumab, respectively
7,8 
(Figure 2). The feasibility and usefulness of this treatment in the acute 
setting of ACS (within hours/days of symptom onset) has not been previously investigated.     
For patients with inadequate reduction in LDL-C levels despite statin treatment, currently 
recommended approaches include combination with non-statin medications.
6
 Ezetimibe, when added 
to statins, results in 20% incremental LDL-C lowering and a small reduction in cardiovascular 
morbidity.
24
 In patients requiring a greater magnitude of LDL-C lowering to achieve recommended 
targets, PCSK9 inhibitors are a reasonable therapeutic option as they can lower LDL-C by >50%. 
Initiation of PCKS9 inhibitor treatment in the acute phase of ACS has not been studied previously, 
and the EVOPACS trial was designed to fill this gap in evidence by addressing the safety and LDL-C-
lowering efficacy of evolocumab in this setting. While centrally adjudicated cardiovascular outcomes 
are a pre-specified, exploratory endpoint in EVOPACS, the study is not powered to assess clinical 
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outcomes. Larger studies will be required to evaluate whether the impact of PCK9 inhibitors on 
cardiovascular morbidity, as reported in patients with more stable manifestations of atherosclerotic 
CVD,
7,8
 holds true in the acute phase of ACS.   
In animal studies, hepatic mRNA expression and plasma levels of PCSK9 increase over time 
following acute MI.
25
 Consistently, plasma levels of PCSK9 are increased in patients with MI 
compared with stable coronary artery disease (CAD).
26 
Pharmacokinetic studies with PCSK9 
inhibitors have shown rapid reductions in PCSK9 levels, immediately followed by consistent 
reductions in LDL-C levels.
27
 If administered during the acute phase of ACS, as in the present study, 
the effect of PCSK9 inhibitors would be expected to occur at the time point of peak levels of the 
PCSK9 enzyme, thereby potentially enabling early-onset and sustained reduction of LDL-C levels.  
Previous studies with PCSK9 inhibitors included stable, primary- or secondary-prevention 
patients and typically applied a run-in period for up-titration of statins, to ensure the inclusion of 
patients with elevated LDL-C levels despite maximally tolerated statin therapy. EVOPACS will 
assess PCSK9-inhibitor treatment initiated in the acute phase of ACS; based on the study design, a 
run-in period is not possible. However, the LDL-C cut-offs defining eligibility for study participation 
are based on robust evidence regarding the LDL-C-lowering potential of atorvastatin 40mg,
6
 either as 
a newly initiated treatment (in statin-naïve patients) or in the context of treatment escalation (in 
patients treated with lower-intensity statin regimens prior to enrolment). Despite inherent limitations 
of these assumptions, our approach will ensure with reasonable certainty that patients with LDL-C 
levels above currently recommended targets despite intensive (pre-existing, or newly established) 
statin treatment are enrolled. Regarding tolerability of high-dose atorvastatin, although subjects with 
reported statin intolerance are excluded from the study, it is possible that some of the enrolled patients 
(especially those never exposed to a statin prior to enrolment) may develop statin-related side effects. 
However, considering the short duration of the study and the usually more delayed pattern of onset of 
reported side effects with statins
28
, it is reasonable to expect that statin intolerance (possibly requiring 
de-escalation or cessation of the background statin treatment) will not occur frequently and thus will 
not have a substantive confounding effect on the study outcomes.      
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 Statins and ezetimibe reduce levels of inflammatory biomarkers,
10,29
 and several studies have 
reported improved cardiovascular outcomes in the presence of hs-CRP reduction.
30
 In experimental 
atherosclerosis, alirocumab reduces monocyte recruitment and inflammatory infiltrations.
31
 In 
humans, plasma levels of PCSK9 correlate with levels of CRP, and knockdown of PCSK9 attenuates 
the expression of pro-inflammatory genes in macrophages.
32
 In the context of ACS, in particular, 
there appears to be a cross-reaction between PCSK9 and oxidized LDL-C that leads to a mutually 
amplified pro-inflammatory response.
33
 Although previous studies showed no significant effect of 
PCSK9 inhibitors on CRP levels,
34
 these results need to be interpreted in view of previous study 
populations including patients with familial hypercholesterolemia (in whom markedly increased LDL-
C levels are not coupled with systemic inflammatory activation
35
) or primary-prevention patients 
without CAD and without elevated baseline levels of CRP. Along these lines, studies of statins have 
reported modest CRP lowering in primary-prevention or stable CAD patients (between 14% and 
36%)
36
 vs. substantial (8- to 10-fold) reductions in patients with ACS.
10,29
 Against this background, 
the EVOPACS study will test the hypothesis that evolocumab suppresses inflammation and reduce 
levels of inflammatory biomarkers in patients with ACS – an acute setting characterized by marked 
inflammatory activation.     
 Despite potent antiplatelet therapies, residual platelet reactivity may occur in a proportion of 
treated ACS patients, thus increasing the risk of recurrent ischemic events.
37
 Multiple pathways are 
involved in platelet activation and fibrin synthesis in this setting. High levels of LDL-C (particularly 
oxidized LDL) correlate with plasma fibrinogen levels and platelet activation.
38
 Statins inhibit platelet 
aggregation, reduce platelet-mediated thrombus formation,
39
 augment the pharmacodynamic response 
to antiplatelet agents, and attenuate platelet reactivity in patients undergoing PCI.
13
 Notably, the 
PCSK9 enzyme is associated with upregulation of tissue factor expression and increased 
lipoprotein(a) levels,
40
 thus promoting a prothrombotic milieu, and plasma levels of PCSK9 correlate 
with increased platelet count and activation
41
 in ACS patients treated with ticagrelor or prasugrel. By 
increasing LDL-C clearance from the circulation and reducing lipoprotein(a), one can speculate that 
PCSK9 inhibitors might attenuate platelet reactivity induced by native and oxidized LDL-C.
19
 This 
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putative platelet-inhibitory effect of PCSK9 inhibitors has not been previously explored and will be 
tested in this study.   
Patients with ACS undergoing coronary angiography are at high risk of developing CI-AKI, a 
relevant complication that adversely affects clinical prognosis. Statins reduce the risk CI-AKI, and 
this protective effect appears to be in part unrelated to their lipid-lowering potential. PCSK9 inhibitors 
exert antioxidant, anti-inflammatory,
17
 and anti-apoptotic properties
42 
similar to statins according to 
preclinical investigations. The EVOPACS study will explore, in a modestly sized ACS population, 
whether these mechanistic effects translate into prevention of renal damage in patients exposed to 
iodinated contrast medium.   
 
Conclusion    
Patients with ACS are at particularly high cardiovascular risk and require aggressive risk factor 
management. Because many ACS patients cannot achieve adequate LDL-C lowering with statins, 
substantial residual risk remains. Moreover, in view of the delayed onset of action of statins and the 
early risk of recurrent events following an ACS, early initiation of PCSK9-inhibitors (i.e., rapidly 
acting, highly potent LDL-lowering agents) may be of clinical value in this setting. The EVOPACS 
trial will provide new insights into the safety and efficacy of evolocumab in the acute setting of ACS, 
and thus improve our understanding of the potential role of PCSK9 inhibition in the management of 
these patients.
43
 In addition, the study will explore mechanistic evidence regarding potential beneficial 
effects of PCSK9 inhibition beyond the primary impact on LDL-C in the ACS setting.    
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FIGURE LEGENDS  
 
Figure 1. Study design for EVOPACS.  
 
 
Figure 2. Timing of patient enrolment following the index acute coronary event in EVOPACS (red 
dotted line) vs. the FOURIER and ODYSSEY OUTCOMES trials. ACS indicates acute coronary 
syndrome; CAD, coronary artery disease; and MI, myocardial infarction.   
 
 
 
Table 1. Inclusion criteria   
Male or female ≥ 18 years of age  
Hospitalized for a recent ACS (unstable angina or NSTEMI within < 72 hours, STEMI within < 24 
hours prior to screening) 
LDL-C levels at screening:  
 LDL-C ≥70 mg/dL (≥1.8 mmol/L) or non-HDL-C ≥100 mg/dL (≥2.6 mmol/) in patients who 
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have been receiving stable treatment with high-intensity statin within ≥ 4 weeks prior to 
enrolment (i.e. continuous treatment that has not changed with regard to statin intensity over 
the past 4 weeks) or 
 LDL-C ≥90 mg/dL (≥2.3 mmol/L) or non-HDL-C ≥120 mg/dL (≥3.1 mmol/) in patients who 
have been receiving stable treatment with low- or moderate-intensity statin within ≥ 4 weeks 
prior to enrolment (i.e. continuous treatment that has not changed with regard to statin 
intensity over the past 4 weeks) or  
 LDL-C ≥125 mg/dL (≥3.2 mmol/L) or non-HDL-C ≥155 mg/dL (≥4.0 mmol/) in patients 
who are statin-naïve or have not been on a stable (unchanged) statin regimen for at least 4 
weeks prior to enrolment.  
Ability to understand the requirements of the study and to provide informed consent 
 
 
 
 
 
 
 
 
Table 2. Main exclusion criteria   
Unstable clinical status (hemodynamic or electrical instability) 
Uncontrolled cardiac arrhythmia, defined as recurrent and symptomatic ventricular tachycardia or 
atrial fibrillation or flutter with rapid ventricular response not controlled by medications in the past 
3 months prior to screening 
Severe renal dysfunction, defined by estimated glomerular filtration rate <30 ml/min/1.73m2 
Active liver disease or hepatic dysfunction, either reported in patient medical record or defined by 
asparate aminotransferase (AST) or alanine aminotransferase (ALT) levels > 3x the upper limit of 
normal 
Known allergy to contrast medium, heparin, aspirin, ticagrelor or prasugrel 
Reported intolerance to atorvastatin (any dose) or statin intolerance defined by the following 
criteria: inability to tolerate at least 2 different statins; intolerance associated with confirmed, 
intolerable statin-related adverse effect(s) or significant biomarker abnormalities; symptom or 
biomarker changes resolution or significant improvement upon dose decrease or discontinuation; 
and symptoms or biomarker changes not attributable to established predispositions  
Patients who previously received evolocumab or another PCSK9 inhibitor  
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Patient who received cholesterol ester transfer protein inhibitors within 12 months prior to 
screening 
Treatment with systemic steroids or systemic cyclosporine in the past 3 months (e.g. intravenous, 
intramuscular or per os) 
Known active infection or major hematologic, metabolic, or endocrine dysfunction in the judgment 
of the Investigator 
Ability to understand the requirements of the study and to provide informed consent 
Current enrolment in another investigational device or drug study 
Active malignancy requiring treatment 
Pregnancy. For females of childbearing potential (age <50 years and last menstruation <12 months 
prior to screening) who did not undergo tubal ligation, ovariectomy or hysterectomy, pregnancy 
will be excluded by a pregnancy test prior to inclusion in the study. 
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